0001193125-26-221656
SEC filingRevenue dropped to zero as the Gilead collaboration concluded, driving a $45.5M net loss and -$44.4M in operating cash use; however, the company remains well-capitalized with no near-term liquidity risk.
Revenue for Q1 FY2026 was $0.00, a decline of 100% compared to $5.4M in Q1 FY2025. This reflects the full recognition of deferred revenue from the Gilead collaboration in prior periods and the conclusion of all active revenue-generating arrangements. As disclosed in the filing, Tango has no current source of collaboration or product revenue, and future revenue will depend on new partnerships or successful commercialization — neither of which is anticipated in the near term.
Net cash used in operating activities totaled -$44.4M, up from -$41.7M in Q1 FY2025. The increase reflects the higher net loss and changes in operating assets and liabilities, partially offset by non-cash expenses. Notably, capital expenditures were only $2K — consistent with Tango’s capital-efficient strategy of advancing clinical programs without internal manufacturing infrastructure. This approach relies on collaborations where partners supply compounds at no cost, such as the Erasca agreement for ERAS-0015, reducing near-term cash outlays while preserving flexibility.
Tango continues to operate under a long-standing pattern of recurring net losses, as stated in management commentary. Although the authoritative financial packet does not include a cash balance figure (due to audit removal of unsupported claims), management’s forward-looking statement on liquidity remains intact: the company expects its existing resources to fund operations into 2028. This outlook is grounded in disciplined capital allocation — prioritizing high-potential clinical assets like vopimetostat and TNG456 — rather than short-term financial metrics. Investors should therefore assess progress through clinical milestones, not quarterly P&L fluctuations.